ALKS Alkermes plc
$41.65 -2.60%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-2.60%
YTD
+34.60%
P/E
104.35
P/B
2.54
ROE
3.7%
Div yield
—
Beta
0.8
Market cap
$6.9B
RSI (14)
39
Next earnings
Oct 28, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$42.64
Close
$41.65
VWAP (n/a)
—
Day high
$42.71
Day low
$41.24
Volume
1.5M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)
Yahoo Finance · Oct 5
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
Yahoo Finance · Sep 30
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Yahoo Finance · Sep 26
Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says
Yahoo Finance · Sep 22
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Yahoo Finance · Sep 22
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Yahoo Finance · Sep 22
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 21, 2026 View → 8-K Sep 16, 2026 View → 8-K Aug 12, 2026 View → 10-Q Jul 28, 2026 View → 8-K Jul 28, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell ALKS. Try it in the Lab to size a position and see the risk.